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Pulmonary arterial hypertension (PAH) is a progressive disease characterized by elevated
pulmonary vascular resistance (PVR) leading to right heart failure and premature death.
The increased PVR results in part from pulmonary vascular remodeling and sustained
pulmonary vasoconstriction. Excessive pulmonary vascular remodeling stems from
increased pulmonary arterial smooth muscle cell (PASMC) proliferation and decreased
PASMC apoptosis. A rise in cytosolic free Ca2+ concentration ([Ca2+]cyt) in PASMC is a
major trigger for pulmonary vasoconstriction and a key stimulus for PASMC proliferation
and migration, both contributing to the development of pulmonary vascular remodeling.
PASMC from patients with idiopathic PAH (IPAH) have increased resting [Ca2+]cyt
and enhanced Ca2+ influx. Enhanced Ca2+ entry into PASMC due to upregulation of
membrane receptors and/or Ca2+ channels may contribute to PASMC contraction and
proliferation and to pulmonary vasoconstriction and pulmonary vascular remodeling. We
have shown that the extracellular Ca2+-sensing receptor (CaSR), which is a member of
G protein-coupled receptor (GPCR) subfamily C, is upregulated, and the extracellular
Ca2+-induced increase in [Ca2+]cyt is enhanced in PASMC from patients with IPAH
in comparison to PASMC from normal subjects. Pharmacologically blockade of CaSR
significantly attenuate the development and progression of experimental pulmonary
hypertension in animals. Additionally, we have demonstrated that dihydropyridine Ca2+
channel blockers (e.g., nifedipine), which are used to treat PAH patients but are only
effective in 15–20% of patients, activate CaSR resulting in an increase in [Ca2+]cyt in
IPAH-PASMC, but not normal PASMC. Our data indicate that CaSR functionally couples
with transient receptor potential canonical (TRPC) channels to mediate extracellular
Ca2+-induced Ca2+ influx and increase in [Ca2+]cyt in IPAH-PASMC. Upregulated CaSR
is necessary for the enhanced extracellular Ca2+-induced increase in [Ca2+]cyt and the
augmented proliferation of PASMC in patients with IPAH. This review will highlight the
pathogenic role of CaSR in the development and progression of PAH.
Keywords: Ca2+-sensing receptor, store-operated calcium channel, smooth muscle cells, G-protein coupled
receptor, pulmonary artery, pulmonary arterial hypertension
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INTRODUCTION
Under normal physiological conditions, the pulmonary
circulation is maintained in a high flow, low pressure, and
low resistance state. During conditions of increased blood
flow or cardiac output (e.g., during exercise), vasodilation
and recruitment (opening of closed blood vessels) of
pulmonary arteries are two important mechanisms for
reducing pulmonary vascular resistance (PVR). However,
under pathological conditions, increased PVR is a major cause
for the development of pulmonary hypertension. Elevated PVR
over time leads to right ventricular hypertrophy and right heart
failure.
Pulmonary hypertension is defined by a mean pulmonary
arterial pressure (PAP) ≥25 mmHg at rest, as measured by
right heart catheterization. Pulmonary arterial hypertension
(PAH) describes a subpopulation of patients with pulmonary
hypertension, and is hemodynamically defined by a resting
mean PAP ≥25 mmHg, pulmonary arterial wedge pressure ≤15
mmHg, and PVR >3 Wood units (equivalent to mmHg·min/l)
(Hoeper et al., 2013). Under the current clinical classification
system established at the fifth World Symposium on Pulmonary
Hypertension held in Nice, France in 2013, PAH comprises a
group of uncommon conditions characterized by obliterative
vasculopathy of the small pulmonary arteries. PAH can be
idiopathic (IPAH, when no etiological factors are identified),
heritable, induced by drugs or toxins, or be related to
conditions, such as connective tissue diseases, congenital heart
diseases, portal hypertension, or HIV infection (Simonneau
et al., 2013). The population prevalence of PAH is estimated
15–50 cases per million, and the incidence is 2–7 cases per
million, making PAH a rare disease (Humbert et al., 2006;
Peacock et al., 2007). According to the Registry to Evaluate
Early and Long-term PAH Disease Management (REVEAL
Registry), an observational US disease registry providing
current information about demographics, disease course, and
management of patients with PAH, the mean age at diagnosis
of PAH is 50.1 ± 14.4 years, with a female to male ratio
of 3:1 and a 5-year survival rate from time of diagnosis of
57% (Mcgoon et al., 2008; Badesch et al., 2010; Farber et al.,
2015).
PATHOLOGICAL CHANGES IN THE
PULMONARY VASCULATURE IN PATIENTS
AND ANIMALS WITH PULMONARY
HYPERTENSION
Although the subcategories of PAH originate from different
underlying causes, all forms of PAH can be characterized by a
combination of sustained pulmonary vasoconstriction, excessive
pulmonary vascular remodeling, in situ thrombosis, and arterial
wall stiffening (Humbert et al., 2004; Schermuly et al., 2011).
Patients with PAH have been shown to have reduced levels of
vasodilatory mediators, such as prostaglandin I2 and nitric oxide,
and increased levels of the potent vasoconstrictors thromboxane,
rho-kinase, and endothelin 1 (Christman et al., 1992; Steudel
et al., 1997). Additionally, in patients with IPAH and animals
with experimental pulmonary hypertension, abnormalities in
K+ and Ca2+ channels have been linked with pathological
pulmonary vasoconstriction (Yuan et al., 1998; Yu et al.,
2004).
Controlling the balance between cell proliferation and
apoptosis of pulmonary arterial fibroblasts, pulmonary
arterial smooth muscle cells (PASMC), and pulmonary arterial
endothelial cells is essential for maintaining normal structural
and functional integrity of the pulmonary vasculature. If the
balance is tipped in favor of cell proliferation, thickening of
the wall, luminal narrowing, and eventual obliteration can
occur. These structural changes that lead to hypertrophy
and/or luminal occlusion are referred to as pulmonary vascular
remodeling (Yu et al., 2004; Masri et al., 2007). The cellular
and molecular mechanisms that lead to vascular remodeling are
extremely complex, however it is generally understood that K+
channels play a pivot role in this process as they are regulators
of vessel tone, cell proliferation and apoptosis. Downregulation
of K+ channels is linked to sustained depolarization due
to enhanced Ca2+ entry and diminished K+ eﬄux, which
promotes cell proliferation and inhibits apoptosis, respectively.
Increased proliferation and hypertrophy of PASMC have been
implicated in the development of PAH and these processes, like
vasoconstriction, relate in part to disturbed Ca2+ homeostasis
(Kuhr et al., 2012). We have recently shown that the extracellular
Ca2+-sensing receptor (CaSR) is upregulated in PASMC
and lung tissue from patients with IPAH (Yamamura et al.,
2012).
CHARACTERISTICS OF CaSR AS A GPCR
CaSR is a G-protein coupled receptor (GPCR) and a member
of family C of the GPCR acids. It has a large extracellular
domain that is approximately 600 amino acids long. This large
extracellular domain is composed of a bi-lobed Venus-flytrap-
like domain which is connected to the seven-transmembrane-
domain by a cysteine rich region. The intracellular domain of
CaSR contains the COOH domain which is 216 amino acids
long (Hendy et al., 2009). The CaSR functions as a dimer in
which the venus-flytrap-like domains of each monomer interact.
Ca2+ binds in the cleft of the venus-flytrap-like domain and
causes a conformational change in CaSR which instigates cells
signaling events (Hendy et al., 2009). The CaSR couples to G
proteins to activate or inhibit multiple intracellular signaling
pathways.
CaSR was originally discovered in the parathyroid gland
were it maintains Ca2+ levels in the blood by adjusting
release of parathyroid hormone. When CaSR senses changes
in extracellular Ca2+ levels, parathyroid chief cells release
parathyroid hormone which normalizes Ca2+ levels by its
actions on kidneys, bones, and indirectly, intestines (Brown
et al., 1993; Kurokawa, 1994; Saidak et al., 2009). The primary
physiological functions of CaSR are to detect changes in
extracellular Ca2+ levels, modulate release of parathyroid
hormone, and maintain constant blood Ca2+ levels. CaSR
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is widely expressed and mutations in CaSR have been
associated with several diseases. Inactivating mutations in
CaSR cause familial hypocalciuric hypercalcemia and neonatal
severe hyperparathyroidism, while activating mutations
cause autosomal dominant hypocalcemia and hypocalcemic
hypercalciuria (Hendy et al., 2009).
CaSR SIGNALING
As a member of the Class C family of GPCRs, CaSR signals to
downstream pathways via three main groups of heterotrimeric
G-proteins, Gq/11, Gi/o, and G12/13 (Conigrave and Ward,
2013; Figure 1). CaSR-mediated activation of Gq/11 leads to
activation of phospholipase Cβ (PLCβ) resulting in conversion
of phosphatidylinositol 4,5 bisphosphate to diacylglycerol (DAG)
and inositol 1,4,5-triphosphate (IP3) (Kifor et al., 2001;
Thomsen et al., 2012). This results in an increase in the
intracellular Ca2+ concentration and phosphorylation of protein
kinase C (PKC), which then activates the mitogen-activated
protein kinase (MAPK) signaling cascade ultimately resulting in
phosphorylation and activation of ERK1/2 (Kifor et al., 2001;
Thomsen et al., 2012). CaSR-mediated activation of Gi/o results
in inhibition of adenylate cyclase (AC) leading to decreased
conversion of ATP to cAMP and decreased protein kinase A
activity (Kifor et al., 2001; Thomsen et al., 2012). The β/γ subunits
of Gi/o activate Ras leading to MAPK activation and ERK1/2
phosphorylation. Upon activation of CaSR, the GTP-bound α
subunit of G12/13 causes RhoGEF to translocate to the plasma
membrane and activates its guanine nucleotide exchange factor
(GEF) activity. RhoGEF then activates RhoA by catalyzing the
exchange of GDP for GTP (Siehler, 2009). Downstream targets
of RhoA include ROCK which mediates cell contraction by
inhibiting myosin light chain phosphatase activity, resulting in
increased myosin light chain phosphorylation. ROCK also plays
a critical role in the polymerization and stabilization of actin
filaments by direct activation of mDia (mammalian homolog
of Drosophila diaphanous) and indirect phosphorylation of the
depolymerizing factor cofilin, respectively (Jernigan and Resta,
2014).
CaSR-mediated activation of downstream signaling pathways
results in increased intracellular Ca2+ concentration, increased
Ca2+ sensitivity, cell contraction, and cell proliferation
(Figure 2). Increased synthesis of IP3 and DAG results in
the binding of IP3 to the IP3 receptor (IP3R) on the sarcoplasmic
reticulum (SR) releasing Ca2+ from the SR to the cytosol. In
PASMC, depletion of Ca2+ from the SR induces store-operated
Ca2+ entry (SOCE) through store-operated Ca2+ channels
(SOC). DAG activates receptor-operated Ca2+ channels (ROC)
in the plasma membrane resulting in receptor-operated Ca2+
entry (ROCE). A rise in cytosolic free Ca2+ concentration
([Ca2+]cyt) in PASMC is a major trigger for pulmonary
vasoconstriction and a key stimulus for PASMC proliferation.
Several studies have demonstrated that resting [Ca2+]cyt,
SOCE, and ROCE are all increased in PASMC isolated from
IPAH patients (Yu et al., 2004; Zhang et al., 2007; Song et al.,
2011).
FIGURE 1 | Generalized representation of CaSR-mediated signaling pathways. CaSR signals to downstream pathways via three main groups of heterotrimeric
G-proteins, Gq/11, Gi/o, and G12/13. CaSR-mediated activation of Gq/11 leads to activation of PLCβ resulting in production of IP3 which mobilizes cytosolic Ca
2+
from intracellular Ca2+ stores and phosphorylation of PKC, thereby activating MAPK and subsequent phosphorylation and activation of ERK1/2. CaSR-mediated
activation of Gi/o inhibits AC, which reduces levels of cAMP and PKA activity. The β/γ subunits of Gi/o activate Ras leading to MAPK activation and ERK1/2
phosphorylation. Activation of G12/13 causes RhoGEF to translocate to the plasma membrane where it activates GEF. RhoGEF then activates RhoA by catalyzing the
exchange of GDP for GTP.
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FIGURE 2 | CaSR-mediated activation of downstream signaling pathways results in increased intracellular Ca2+ concentration, increased Ca2+
sensitivity, cell contraction, and cell proliferation. Increased synthesis of IP3 and DAG results in elevated [Ca
2+]cyt via Ca
2+ release and Ca2+ entry. IP3 binds
to the IP3R on the SR releasing Ca
2+ from the SR to the cytosol. Depletion of Ca2+ from the SR induces SOCE through SOCs. DAG activates ROCs in the plasma
membrane resulting in ROCE. This rise in [Ca2+]cyt in PASMC is a major trigger for pulmonary vasoconstriction and a key stimulus for PASMC proliferation.
UPREGULATED EXPRESSION AND
ENHANCED FUNCTION OF CaSR IN
PATIENTS WITH IPAH AND ANIMALS WITH
EXPERIMENTAL PH
Our studies have demonstrated that application of extracellular
Ca2+ increased [Ca2+]cyt in PASMC isolated from IPAH
patients compared to PASMC from control patients and
patients with chronic thromboembolic pulmonary hypertension
(Yamamura et al., 2012). We found that this is due to
increased expression of CaSR in PASMC and lung tissues from
patients with IPAH. The extracellular Ca2+-induced increase
in [Ca2+]cyt in IPAH PASMC is dependent on PLC and
IP3R. Downregulation of CaSR in IPAH PASMC via siRNA
reversed the extracellular Ca2+-induced increase in [Ca2+]cyt
and attenuated the enhanced proliferation of IPAH PASMC
(Yamamura et al., 2012). Additionally, overexpression of CaSR
augmented the extracellular Ca2+-induced increase in [Ca2+]cyt
and enhanced proliferation in normal PASMC (Yamamura et al.,
2012). These data demonstrate that increased expression of CaSR
and subsequently enhanced CaSR-mediated [Ca2+]cyt increase
contribute to the enhanced Ca2+ signaling and proliferation of
PASMC in patients with IPAH.
Using two experimental models of PH, we confirmed the
role of CaSR in the development of PH. CaSR mRNA and
protein levels are increased in PASMC and small pulmonary
arteries in the rat model of monocrotoline-induced pulmonary
hypertension (MCT-PH) compared to vehicle injected control
rats. Additionally, resting [Ca2+]cyt and extracellular Ca
2+-
induced increase in [Ca2+]cyt were both enhanced in PASMC
from MCT-PH rats, implying that functional upregulation of
CaSR in PASMC contributes to the development of pulmonary
hypertension in rats injected with MCT (Yamamura et al., 2012).
Similar results were seen in the mouse model of hypoxia-induced
pulmonary hypertension (HPH). Expression of CaSR mRNA
and protein was significantly increased in HPH mice than in
normoxic control mice, and extracellular Ca2+-induced increase
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in [Ca2+]cyt was significantly enhanced in PASMC isolated from
HPH mice (Yamamura et al., 2012). These data suggest that
CaSR is functionally upregulated in PASMC from HPH mice.
Pharmacological blockade of CaSR with NPS 2143, a CaSR
antagonist, significantly attenuated the development of PH in
both the rat MCT-PH model and the mouse HPH model.
Treatment with NPS 2143 significantly inhibited the increase
in right ventricular systolic pressure (RVSP, an indicator of
pulmonary arterial pressure) and inhibited the ratio of the weight
of the right ventricle to left ventricle plus septum (Fulton’s index,
an indicator of right ventricular hypertrophy) in MCT-PH rats
and HPH mice (Yamamura et al., 2012). Collectively, these data
indicate that increased expression of CaSRmay play a pathogenic
role in the development of PH and that antagonists of CaSR may
therapeutic potential for patients with PH.
CaSR FUNCTIONALLY COUPLES TO TRPC
CHANNELS TO REGULATE [Ca2+]CYT IN
PATIENTS WITH IPAH AND ANIMALS WITH
EXPERIMENTAL PH
Upon activation by extracellular stimuli, CaSR induces activation
of downstream signaling pathways which result in increased
[Ca2+]cyt. The increased [Ca
2+]cyt results from Ca
2+ release
from intracellular stores and Ca2+ influx through ROC and
SOC. Transient receptor potential conical (TRPC) channels have
been shown to function as both ROC and SOC in PASMC
(Yu et al., 2003, 2004). We recently discovered that CaSR
functionally interacts with TRPC6 channels in PASMC from
IPAH patients and animals with experimental PH and may
play important role in the development and progression of
sustained pulmonary vasoconstriction and pulmonary vascular
remodeling (Tang et al., 2016). As discussed earlier, extracellular
Ca2+-induced increase in [Ca2+]cyt is enhanced in IPAH-
PASMC due to increased expression of CaSR (Yamamura
et al., 2012). Blockade of TRPC6 channels significantly inhibits
extracellular Ca2+-induced increase in [Ca2+]cyt in IPAH-
PASMC (Tang et al., 2016). Overexpression of CaSR or TPRC6 in
normal PASMC results in enhanced extracellular Ca2+-induced
increase in [Ca2+]cyt, however, overexpression of both CaSR
and TRPC6 dramatically increases extracellular Ca2+-induced
increase in [Ca2+]cyt compared to either alone (Tang et al.,
2016). These data strongly suggest that CaSR is functionally
coupled to TRPC6 channels in IPAH-PASMC and that receptor—
and store-operated Ca2+ entry via CaSR-mediated activation
of TRPC6 is an important signaling cascade which leads to
PASMC contraction, proliferation, andmigration in patients with
IPAH.
Studies in experimental models of PH revealed that CaSR
plays a role in the development of PH. Using CaSR and
parathyroid hormone double knockout mice (casr−/−/pth−/−;
casr−/− mice are embryonic lethal) (Ho et al., 1995; Kos
et al., 2003), we demonstrated that deletion of CaSR inhibited
the development of PH in mice exposed to chronic hypoxia.
Exposure of casr−/− mice (i.e., casr−/−/pth−/− mice) to
chronic hypoxia results in attenuated RVSP, Fulton’s Index,
and pulmonary arterial wall thickness compared to chronically
hypoxic wildtype mice (Tang et al., 2016).
TARGET CaSR TO DEVELOP NOVEL
THERAPEUTIC APPROACH FOR PAH
Calcium channel blockers (CCBs) have been successfully
administered as a long term therapy to a number of PAH
patients who respond positively to acute vasodilator challenge
(Puri et al., 2007). Unfortunately only 10–15% of PAH patients
actually meet the criteria, and within this subgroup only about
half the patients exhibit any sustained benefit from using CCBs
(Sitbon et al., 2005). Due to advances in the understanding
of the pathological mechanisms of PAH, drug therapy for
PAH has progressed in recent years via the development of
several specific drugs that offer an effective alternative to CCBs,
such as nifedipine and diltiazem. Most recently, efforts have
turned toward the use of CaSR antagonists, also known as
calcilytics, as potential drug candidates for treatment of PAH.
Two structurally distinct calcilytics NPS2143 and Calhex 231
were shown to suppress excessive cell proliferation of IPAH-
PASMCs, but not in normal or CTEPH (chronic thromboembolic
pulmonary hypertension) PASMCs, whereas R568, an activator of
CaSR, significantly enhanced the proliferation of IPAH-PASMCs
(Yamamura et al., 2015). Additionally, NPS2143 but not R568
was shown to attenuate, the extracellular Ca2+-induced [Ca2+]cyt
rise in IPAH-PASMC. Furthermore, intraperitoneal injection of
NPS2143 prevented the development of pulmonary hypertension
and right ventricular hypertrophy in MCT-PH rats and CH-PH
mice (Yamamura et al., 2012). Phosphodiesterase type 5 (PDE5)
inhibitors are widely used to treat IPAH patients. Sildenafil
inhibits excessive cell proliferation of IPAH-PASMC, but does
not affect the cell growth of PASMC from normal subjects and
CTEPH patients. In combination with NPS2143 or Calhex 231,
the antiproliferative effect induced by sildenafil was significantly
enhanced in IPAH-PASMC (Yamamura et al., 2016). These
findings reveal that CaSR antagonists and PDE5 inhibitors work
together to additively suppress the excessive cell proliferation of
IPAH-PASMC, suggesting that a combination therapy of a PDE5
inhibitor with a calcilytic may be useful as a novel therapeutic
approach for IPAH.
SUMMARY AND CONCLUSION
An atypical rise in [Ca2+]cyt is a major cause for sustained
pulmonary vasoconstriction, and excessive pulmonary vascular
remodeling observed in patients of IPAH. Our group has
previously shown that expression of CaSR, a member of the
GPCR family, is upregulated in PASMC isolated from IPAH
patients and in animal models of pulmonary hypertension.
Additionally, CaSR has been shown to be necessary for
the increased extracellular Ca2+ influx and subsequent
elevation of [Ca2+]cyt, that in turn leads to enhancement of
cellular proliferation, contraction, and migration in IPAH-
PASMC. Therefore, it is feasible to say that upregulated
CaSR in PASMC presents a novel pathogenic mechanism
Frontiers in Physiology | www.frontiersin.org 5 November 2016 | Volume 7 | Article 517
Smith et al. Calcium-Sensing Receptor and Pulmonary Vascular Disease
contributing to sustained vasoconstriction and excessive
vascular remodeling seen in IPAH patients. Our group has also
shown that CaSR regulates ROCE and SOCE via activation
of TRPC6 in IPAH-PASMC from patients and animals with
experimental pulmonary hypertension suggesting a functional
coupling between CaSR and TRPC6. Pharmacological blockade
and targeted deletion of CaSR has been shown to inhibit
the CaSR-mediated increase in [Ca2+]cyt and attenuates the
development of experimental-induced pulmonary hypertension
in animal models of the disease. Thus, pharmacological
targets of CaSR may reveal novel therapeutic strategies
for controlling aberrant Ca2+ signaling observed in PAH
patients.
FUTURE RESEARCH DIRECTION
While it has been demonstrated that both CaSR and TRPC6
are upregulated in PASMC from IPAH patients and animals
with experimental pulmonary hypertension and play a critical
role in the pathogenesis of PAH, it remains unknown
how this is achieved. The human CaSR gene, CASR, can
be transcriptionally regulated by transcription factors, post-
transcriptionally regulated by microRNAs and epigenetically
regulated by DNA methylation (Hendy et al., 2009). The
promoter region of CASR contains numerous binding sites of
transcription factors that are associated with cell proliferation
(Fantozzi et al., 2003; Firth et al., 2010; Crosswhite and Sun,
2014). Not surprisingly, several of these transcription factors
have been demonstrated to be upregulated in PASMC from
patients with IPAH and animals with experimental PH (Yu
et al., 2003; Firth et al., 2010; Crosswhite and Sun, 2014;
Zabini et al., 2015). It is likely these upregulated transcription
factors bind directly to the promoter of CASR and activate
CASR transcription. MicroRNAs (miRNA or miR) are another
area of interest as they can potentially regulate the CaSR
mRNA and protein level by directly binding to the 3′-
UTR of CaSR mRNA thereby decreasing expression levels via
inhibition of protein translation or increase the rate of mRNA
degradation. Using the in silico prediction approach (provided
by microrna.org), we have identified several miRNAs that may
potentially target CASR. Further efforts should focus on in vitro
and in vivo approaches to examine the potential involvement
of upregulated/downregulated miRNAs in the upregulation of
CASR shown in PASMC from IPAH patients and animals with
experimental PH.
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